These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 24570209

  • 1. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [Abstract] [Full Text] [Related]

  • 3. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 4. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z.
    Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
    [Abstract] [Full Text] [Related]

  • 5. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 6. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 7. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P, Brunelli C, Rossi ED, Lanza P, Martini M, Musarra T, Lombardi CP, Pontecorvi A, Fadda G.
    Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
    [Abstract] [Full Text] [Related]

  • 8. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Fadda G, Larocca LM, Schmitt F.
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [Abstract] [Full Text] [Related]

  • 9. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H, Zhang ZH, Zhou B, Xiao T, Pan QJ, Guo HQ.
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [Abstract] [Full Text] [Related]

  • 10. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE, Kim LT, Hackman TG, Dodd LG.
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [Abstract] [Full Text] [Related]

  • 11. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.
    Rossi ED, Martini M, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G.
    Cancer Cytopathol; 2014 Jul; 122(7):527-35. PubMed ID: 24639117
    [Abstract] [Full Text] [Related]

  • 12. [Value of the detection of BRAF(V600E) gene mutation and protein expression in auxiliary cytological diagnosis of papillary thyroid carcinoma].
    Zhao H, Guo HQ, Zhang ZH, Cao J, Zhao LL, Sun Y, Wang C, Xiao T.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan 07; 54(1):18-22. PubMed ID: 30704164
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer.
    Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares AH, Friedlander P, Miccoli P, Kandil E.
    Surgery; 2017 Apr 07; 161(4):1122-1128. PubMed ID: 27919446
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 Apr 07; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 15. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, Wang L.
    Pathol Res Pract; 2018 Feb 07; 214(2):303-307. PubMed ID: 29254799
    [Abstract] [Full Text] [Related]

  • 16. Morphological features that can predict BRAFV600E -mutated carcinoma in paediatric thyroid cytology.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM.
    Cytopathology; 2017 Feb 07; 28(1):55-64. PubMed ID: 27256275
    [Abstract] [Full Text] [Related]

  • 17. The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer.
    Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K.
    Endokrynol Pol; 2016 Feb 07; 67(1):35-40. PubMed ID: 26884113
    [Abstract] [Full Text] [Related]

  • 18. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
    Lee SR, Yim H, Han JH, Lee KB, Lee J, Soh EY, Kim DJ, Chung YS, Jeong SY, Sheen SS, Park SH, Kim JH.
    Am J Clin Pathol; 2015 Mar 07; 143(3):437-44. PubMed ID: 25696803
    [Abstract] [Full Text] [Related]

  • 19. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST, Kim SW, Ki CS, Jang JH, Shin JH, Oh YL, Kim JW, Chung JH.
    J Clin Endocrinol Metab; 2012 Jul 07; 97(7):2299-306. PubMed ID: 22500044
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.
    Hum Pathol; 2013 Nov 07; 44(11):2563-70. PubMed ID: 24071017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.